A5089243471- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- HIV/AIDS drug development and treatment
- Liver Disease and Transplantation
- Systemic Lupus Erythematosus Research
- Cancer Immunotherapy and Biomarkers
- Liver Diseases and Immunity
- Immune Cell Function and Interaction
- Endometrial and Cervical Cancer Treatments
- Immunotherapy and Immune Responses
- Influenza Virus Research Studies
- Viral gastroenteritis research and epidemiology
- MRI in cancer diagnosis
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Esophageal Cancer Research and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Chronic Lymphocytic Leukemia Research
- Renal cell carcinoma treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Diet, Metabolism, and Disease
- Animal Virus Infections Studies
Toranomon Hospital
2015-2024
Nagoya City University
2014-2023
Fukushima Medical University
2014-2023
Keio University
1998-2023
Suzuki (Japan)
2023
Ashikaga Red Cross Hospital
2019-2023
LTT Bio-Pharma (Japan)
2022
University of Aizu
2022
Tokyo Medical Center
2022
National Hospital Organization
2022
Chronic hepatitis B virus (HBV) infection leads to cirrhosis and hepatocellular carcinoma (HCC). Antiviral agents are thought reduce HCC development, but such as lamivudine (LAM) have a high rate of drug resistance. We compared the incidence in 472 entecavir (ETV)-treated patients 1,143 nontreated HBV (control group). Propensity score matching eliminated baseline differences, resulting sample size 316 per cohort. The mutation resistance was 0.8% (4/472) ETV group. cumulative rates at 5 years...
All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates current interferon/ribavirin-based regimens. In this open-label, phase 3 study, 135 interferon-ineligible/intolerant 87 nonresponder chronic HCV genotype 1b infection were enrolled at 24 centers in Japan. Patients received daclatasvir 60 mg once daily plus asunaprevir 100 twice weeks. The primary endpoint...
The activity of interferon (IFN) is not elucidated from the viewpoint cancer prevention in chronic hepatitis C patients en masse. hepatocellular carcinogenesis rate was analyzed statistically 1,643 with C: 1,191 IFN therapy and 452 without therapy. Hepatocellular rates treated untreated groups were 2.1% 4.8% at end 5th year, 7.6% 12.4% 10th respectively (P =.0036). Multivariate analysis showed that slightly decreased risk by 33%, compared =. 14), adjusting for confounding effects age,...
Hepatocellular carcinoma (HCC) occurs in patients with hepatitis C virus-RNA positive chronic liver disease. It is important to prevent HCC drug administration.A retrospective study was undertaken evaluate the long term preventive effect of Stronger Neo-Minophagen (SNMC) on development. SNMC a Japanese medicine that commonly administered improve serum alanine aminotransferase (ALT) level. Of 453 diagnosed retrospectively hospital between January 1979 and April 1984, 84 (Group A) had been...
Despite multidisciplinary treatment for patients with advanced gastric cancer, their prognosis remains poor. Therefore, the development of novel therapeutic strategies is urgently needed, and immunotherapy utilizing anti‐programmed death 1/‐programmed ligand‐1 mA b an attractive approach. However, as there limited information on how programmed upregulated tumor cells within microenvironment, we examined mechanism regulation a particular focus interferon gamma in vitro setting clinical...
The aim of this study was to determine the incidence and risk factors hepatocellular carcinoma (HCC), elucidate utility two non-invasive predictive procedures for liver fibrosis: aspartate aminotransferase (AST) platelet ratio index (APRI) BARD score (which includes following three variables: body mass index, AST/alanine ratio, diabetes) in prediction HCC a large population Japanese patients with non-alcoholic fatty disease (NAFLD).This retrospective cohort conducted at public hospital....
Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 91 in core region hepatitis C virus (HCV) genotype 1b can predict response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy telaprevir/PEG-IFN/ribavirin is not clear. The aims this study were investigate predictive factors sustained virological a 12-week or 24-week regimen 72 81 Japanese adults infected with HCV 1. Overall, end-of-treatment achieved by 61% 89%,...
Because hepatocellular carcinoma often recurs after surgical resection or ethanol injection therapy, we conducted a prospective randomized controlled trial of interferon (IFN) in patients with chronic liver disease caused by hepatitis C virus (HCV). Twenty eligible cirrhosis were into two groups: 10 treated 6 million units natural IFN-β twice week for 36 months and without IFN therapy. One patient within the treatment group discontinued therapy 19 because mild degree retinopathy. None either...
<i>Objective:</i> Patients with high titer (≧100 kIU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve highly sustained virological response rates to combination therapy interferon plus ribavirin. Non-virological responders (NVRs, namely ultimate resistant cases) who HCV-RNA negativity during treatment are also encountered. We investigated the pretreatment features NVRs. <i>Methods:</i> evaluated 50 consecutive Japanese adults HCV received for 48 weeks....
Diabetes is present in patients with chronic hepatitis C virus infection. The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors for type 2 diabetes after termination interferon therapy Japanese positive (HCV). A total 2,842 HCV-positive treated (IFN) monotherapy or combination IFN ribavirin were enrolled. mean observation period 6.4 years. An overnight (12-hour) fasting blood sample a casual taken routine analyses during...
Although it has been shown that chemoradiotherapy may induce immunogenic cell death, which could trigger T-cell immunity mediated by high-mobility group box 1 protein (HMGB1) and calreticulin, there is still limited information to support this theory directly in a clinical setting. In the present study, we evaluated antigen-specific responses against six cancer-testis antigens peripheral blood lymphocytes from patients with esophageal squamous carcinoma (ESCC) receiving chemoradiation....
Hepatitis C virus (HCV) genotype 1b and high pretreatment load are predictive factors of poor response to interferon therapy in patients with chronic hepatitis C. To further examine the predicting infection, we analyzed 110 consecutive HCV who were treated a total 624 million units lymphoblastoid alfa. Thirty-six (33%) responders, while remaining 74 (67%) nonresponders. Multivariate analysis showed that titer (assessed by serum core protein level, P = .0021) presence more than two amino acid...
The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors for malignancies after termination interferon (IFN) therapy in Japanese patients hepatitis C virus (HCV). A total 4,302 HCV-positive treated with IFN were enrolled. mean observation period 8.1 years. primary outcome first onset malignancies. Evaluation performed using Kaplan-Meier method Cox proportional hazard analysis. 606 developed malignancies: 393 hepatocellular carcinoma...
The aim of this study was to assess the rate development hepatocellular carcinoma (HCC) in patients who achieved sustained virologic response (SVR) by direct antiviral agents (DAA). We retrospectively evaluated SVR oral DAA interferon-free regimens (n = 77) (daclatasvir/asunaprevir [n 67], ombitasvir/paritaprevir/ritonavir 9], and telaprevir 1]) pegylated-interferon plus ribavirin (Peg-IFN/RBV, n 528). In all patients, background chronic hepatitis or cirrhosis caused HCV genotype 1b. During...
To evaluate the prognostic impact of systemic inflammation score (SIS) in colorectal cancer (CRC) patients comparison with a conventional inflammation-based score, modified Glasgow Prognostic Score (mGPS).The SIS, which is calculated based on preoperative serum albumin level and lymphocyte-to-monocyte ratio, reported marker clear-cell renal cell carcinoma. However, utility SIS CRC remains unclear.The study involved 727 who underwent curative resection between September 2005 December 2011....
Purpose There is growing evidence that tumor-specific immune responses play an important role in anti-cancer therapy, including radiotherapy. Using mouse tumor models we demonstrate irradiation-induced anti-tumor immunity essential for the therapeutic efficacy of irradiation and can be augmented by modulation cytotoxic T lymphocyte (CTL) activity. Methods Materials C57BL/6 mice, syngeneic EL4 lymphoma cells, Lewis lung carcinoma (LL/C) cells were used. Cells injected into right femurs mice....
Amino acid transporters are essential for maintenance and proliferation of both normal transformed cells. In the present study, L‐type amino‐acid transporter 1 (LAT1) immunoreactive expression was investigated in gastric carcinomas, comparison with adenomas non‐neoplastic lesions, using our recently developed novel monoclonal antibody. a total 87 cases advanced cancer, high LAT1 observed carcinoma cells, predominantly at plasma membranes greater intensity non‐scirrhous than scirrhous...
A prospective study based on serial liver biopsies was performed to investigate the efficacy of sodium-glucose cotransporter 2 inhibitor for nonalcoholic fatty disease complicated with type diabetes mellitus. Conclusion: Treatment 24 weeks resulted in improvement histopathologic features all 5 patients. (Hepatology Communications 2017;1:46-52).
The aim of this study was to investigate the therapeutic potential sodium glucose cotransporter 2 inhibitor (SGLT2I) as an effective option for non-alcoholic fatty liver disease (NAFLD).In prospective study, nine patients with NAFLD complicated by type diabetes mellitus (DM), were introduced regimen canagliflozin 100 mg once daily 24 weeks and evaluated histology at pretreatment after start treatment. primary outcome histological improvement, defined a decrease in activity score one point or...